ACADIA Pharmaceuticals Inc. (ACAD)
(Real Time Quote from BATS)
$51.81 USD
+1.33 (2.64%)
Updated Dec 6, 2019 01:20 PM ET
2-Buy 2
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank | Definition | Annualized Return |
---|---|---|
1 2 3 4 5 S&P |
Strong Buy Buy Hold Sell Strong Sell 500 |
24.62% 17.69% 9.40% 5.11% 2.01% 10.65% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
D Value | B Growth | D Momentum | C VGM
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
Value Score | A |
---|---|
Growth Score | A |
Momentum Score | A |
VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.
The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.
The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.
Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
Quote Overview
Stock Activity
Open | 50.51 |
Day Low | 50.50 |
Day High | 52.49 |
52 Wk Low | 14.01 |
52 Wk High | 53.70 |
Avg. Volume | 1,616,094 |
Market Cap | 7.78 B |
Dividend | 0.00 ( 0.00%) |
Beta | 2.81 |
Key Earnings Data
Earnings ESP | 0.00% |
Most Accurate Est | -0.37 |
Current Qtr Est | -0.37 |
Current Yr Est | -1.62 |
Exp Earnings Date | 2/25/20 |
Prior Year EPS | -1.94 |
Exp EPS Growth (3-5yr) NA |
|
Forward PE | NA |
PEG Ratio | NA |
Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.
The technique has proven to be very useful for finding positive surprises. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest.
This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.
Research Report for ACAD
All Zacks’ Analyst ReportsNews for ACAD
- Zacks News for ACAD
- Other News for ACAD
GasLog Partners: Solid Quarter And Growth Potential On Strong LNG Market
ACAD: What are Zacks experts saying now?
Zacks Private Portfolio Services
How The Trade War And Growth Are Impacting Banks Like JPMorgan, Citigroup, And Bank Of America
Citi Private Bank Issues Outlook 2020: Global Growth Can Endure Over the Coming Year
France stocks higher at close of trade; CAC 40 up 0.03%
The Daily Biotech Pulse: Cassava Gains On Alzheimer`s Presentation, Bristol-Myers Hikes Dividend
75 Biggest Movers From Yesterday
Kroger, Sage take losses while Five Below, Acadia advance
Celtics players team up with fans to raise $105,000 for #SunLifeDunk4Diabetes in support of YMCA of Greater Boston's Diabetes Prevention Program
50 Stocks Moving In Thursday`s Mid-Day Session
Premium Research: Industry Analysis
Top Peers | Symbol | Zacks Rank |
---|---|---|
ACADIA Pharmaceuticals Inc. | ACAD | |
Alkermes plc | ALKS | |
Anika Therapeutics Inc. | ANIK | |
Coherus BioSciences, Inc. | CHRS | |
Guardant Health, Inc. | GH | |
Innoviva, Inc. | INVA | |
NuCana PLC Sponsored ADR | NCNA |